СибНСХБ

Вид поиска

Область поиска

Найдено в других БД

Формат представления найденных документов:
библиографическое описание	краткий	полный

Отсортировать найденные документы по:
автору	заглавию	году издания	типу документа

Поисковый запрос: (<.>A=Kostadinov, D. A.$<.>)

Общее количество найденных документов : 4
Показаны документы с 1 по 4

РЖ ВИНИТИ 76 (BI28) 96.01-04Н3.203

Kostadinov, D. A.
Effect of mitomycin C and specific monoclonal antibodies on antigen expression by human melanoma cells in vitro [Text] : [Pap.] Annu. Sci. Sess.'94 NOC[Nat. Oncol. Cent.], 1994 / D. A. Kostadinov // Онкология. - 1994. - Vol. 31, N 1-4. - P15 . - ISSN 0369-7649
Перевод заглавия: Влияние митомицина C и специфических моноклональных антител на экспрессию антигенов клеток меланомы человека in vitro
Аннотация: Human tumor-associated antigens (TAA), particularly cell surface expressed, have attracted attention as the possible targets for tumor therapy with specific monoclonal antibodies (Mabs). An important question is whether the target antigens remain at the cell surface after exposure to the antibody or other therapeutic agents, such as chemotherapy or radiotherapy, or disappear as a result of antigenic modulation. Previously we reported about two mouse Mabs with specificity for human melanoma cells. The Mabs which are of IgG2a and IgG1 isotypes bind to different epitopes, denoted NOC-1 and NOC-2 respectivelly, on the surface of target cells. The aim of this report is to present some data on the effect of these Mabs and one of the most commonly used antitumor drugs Mitomycin C on the expression of NOC epitopes by melanoma cell lines SK MEL 1 and SK MEL 5. Melanoma cells were grown in the presence of unlabeled Mab to one or other epitope or in the presence of Mitomycin C at different doses and then tested for binding of {3}H-leucine labeled Mabs of both specificities. The resuts showed that melanoma cells continued to express the studied epitopes after overnight exposure to the specific Mabs and their level of expression could be increased by treatment with Mitomycin C for 48 hours with low concentrations. Our study indicated also that when the two Mabs are applied simultaneosly in a certain combination their binding activity may be reduced as compared to each single Mab. However, the binding activity night be augmented when the Mabs are applied sequentially to the target cells at an interval of 30-40 min. The consequences of these findings for in vivo applications are discussed.

ГРНТИ	76.29.49

ВИНИТИ 761.29.49.55.21
Рубрики: КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ
ХИМИОТЕРАПИЯ
МИТОМИЦИН C
ИММУНОТЕРАПИЯ
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА
МЕЛАНОМА
АНТИГЕНЫ
ОПУХОЛЕАССОЦИИРОВАННЫЕ
ЭКСПРЕССИЯ

РЖ ВИНИТИ 76 (BI28) 97.07-04Н3.89

Kostadinov, D. A.
Modulation of melanoma-associated antigen expression and shedding induced by mitomycin C in vitro [Text] : [Докл.] на Онкологич. дни, София, 1995 / D. A. Kostadinov // Онкология. - 1995. - Vol. 32, N 3-4. - P20 . - ISSN 0369-7649
Перевод заглавия: Модуляция экспрессии и щеддинга антигена, ассоциированного с меланомой, индуцированная митомицином C in vitro
Аннотация: The importance of chemotherapeutic agents for the treatment of human cancer is well known but their mechanism of action is still matter of debate. In general the antitumor effect of these agents is due to their cytotoxic action on the tumor cells by affecting DNA and/or protein synthesis. Many cancer chemotherapeutic agents, including mitomycin C (MMC), have also the capacity to immunopotentiate. They can augment both cellular and humoral immune responses to new antigens but also augment concomitant antitumor immunity in animal models and in human. This effect may be due to breaching natural and acquired tolerance to tumor antigens and/or to overexpression of these antigens in addition to the selective effects of the agents on immunoregulatory mechanisms. In this presentation it was reported the findings on the antigenic expression of human melanoma cell lines, SK MEL-1 and SK MEL-5, under influence of MMC in vitro. The study revealed some differences in the binding capacity for two specific monoclonal antibodies between the two cell lines, at treating with MMC. Decreased expression of NOC-1 epitope and increased of NOC-2 one following MMC treatment of SK MEL-1 cells in contrast to unchanged expression of both epitopes in SK MEL-5 cells were seen after treatment for up to 48 hrs at 37'ГРАДУС'C with MMC at 1 'мю'g/ml. When cells of the latter line were treated with lower doses (0.01-0.1) increased expression of both epitopes were found. Increased shedding of epitope-bearing molecules was also detected but only where high dose of MMC was used, as high as 100 'мю'g/ml. Taken together the results showed that the effects of chemotherapeutic agents must in general be defined for each tumor to provide optimum benefits for cancer patients in antibody-guided therapy with monoclonal antibodies

ГРНТИ	76.29.49

ВИНИТИ 761.29.49.55.07.11.11.21
Рубрики: МЕЛАНОМА
АНТИГЕНЫ
АНТИГЕН, АССОЦИИРОВАННЫЙ С МЕЛАНОМОЙ
ЭКСПРЕССИЯ
ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА
МИТОМИЦИН С
IN VITRO

РЖ ВИНИТИ 76 (BI29) 97.07-04Н1.371

Kostadinov, D. A.
Modulation of melanoma-associated antigen expression and shedding induced by mitomycin C in vitro [Text] : [Докл.] на Онкологич. дни, София, 1995 / D. A. Kostadinov // Онкология. - 1995. - Vol. 32, N 3-4. - P20 . - ISSN 0369-7649
Перевод заглавия: Модуляция экспрессии и щеддинга антигена, ассоциированного с меланомой, индуцированная митомицином C in vitro
Аннотация: The importance of chemotherapeutic agents for the treatment of human cancer is well known but their mechanism of action is still matter of debate. In general the antitumor effect of these agents is due to their cytotoxic action on the tumor cells by affecting DNA and/or protein synthesis. Many cancer chemotherapeutic agents, including mitomycin C (MMC), have also the capacity to immunopotentiate. They can augment both cellular and humoral immune responses to new antigens but also augment concomitant antitumor immunity in animal models and in human. This effect may be due to breaching natural and acquired tolerance to tumor antigens and/or to overexpression of these antigens in addition to the selective effects of the agents on immunoregulatory mechanisms. In this presentation it was reported the findings on the antigenic expression of human melanoma cell lines, SK MEL-1 and SK MEL-5, under influence of MMC in vitro. The study revealed some differences in the binding capacity for two specific monoclonal antibodies between the two cell lines, at treating with MMC. Decreased expression of NOC-1 epitope and increased of NOC-2 one following MMC treatment of SK MEL-1 cells in contrast to unchanged expression of both epitopes in SK MEL-5 cells were seen after treatment for up to 48 hrs at 37'ГРАДУС'C with MMC at 1 'мю'g/ml. When cells of the latter line were treated with lower doses (0.01-0.1) increased expression of both epitopes were found. Increased shedding of epitope-bearing molecules was also detected but only where high dose of MMC was used, as high as 100 'мю'g/ml. Taken together the results showed that the effects of chemotherapeutic agents must in general be defined for each tumor to provide optimum benefits for cancer patients in antibody-guided therapy with monoclonal antibodies

ГРНТИ	76.29.49

ВИНИТИ 761.29.49.23.07.17.45
Рубрики: МЕЛАНОМА
АНТИГЕНЫ
АНТИГЕН, АССОЦИИРОВАННЫЙ С МЕЛАНОМОЙ
ЭКСПРЕССИЯ
ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА
МИТОМИЦИН С
IN VITRO

РЖ ВИНИТИ 34 (BI39) 97.08-04К1.347

Kostadinov, D. A.
Modulation of melanoma-associated antigen expression and shedding induced by mitomycin C in vitro [Text] : [Докл.] на Онкологич. дни, София, 1995 / D. A. Kostadinov // Онкология. - 1995. - Vol. 32, N 3-4. - P20 . - ISSN 0369-7649
Перевод заглавия: Модуляция экспрессии и щеддинга антигена, ассоциированного с меланомой, индуцированная митомицином C in vitro
Аннотация: The importance of chemotherapeutic agents for the treatment of human cancer is well known but their mechanism of action is still matter of debate. In general the antitumor effect of these agents is due to their cytotoxic action on the tumor cells by affecting DNA and/or protein synthesis. Many cancer chemotherapeutic agents, including mitomycin C (MMC), have also the capacity to immunopotentiate. They can augment both cellular and humoral immune responses to new antigens but also augment concomitant antitumor immunity in animal models and in human. This effect may be due to breaching natural and acquired tolerance to tumor antigens and/or to overexpression of these antigens in addition to the selective effects of the agents on immunoregulatory mechanisms. In this presentation it was reported the findings on the antigenic expression of human melanoma cell lines, SK MEL-1 and SK MEL-5, under influence of MMC in vitro. The study revealed some differences in the binding capacity for two specific monoclonal antibodies between the two cell lines, at treating with MMC. Decreased expression of NOC-1 epitope and increased of NOC-2 one following MMC treatment of SK MEL-1 cells in contrast to unchanged expression of both epitopes in SK MEL-5 cells were seen after treatment for up to 48 hrs at 37'ГРАДУС'C with MMC at 1 'мю'g/ml. When cells of the latter line were treated with lower doses (0.01-0.1) increased expression of both epitopes were found. Increased shedding of epitope-bearing molecules was also detected but only where high dose of MMC was used, as high as 100 'мю'g/ml. Taken together the results showed that the effects of chemotherapeutic agents must in general be defined for each tumor to provide optimum benefits for cancer patients in antibody-guided therapy with monoclonal antibodies

ГРНТИ	34.43.45

ВИНИТИ 341.43.45.05
Рубрики: МЕЛАНОМА
АНТИГЕНЫ
АНТИГЕН, АССОЦИИРОВАННЫЙ С МЕЛАНОМОЙ
ЭКСПРЕССИЯ
ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА
МИТОМИЦИН С
IN VITRO

"Электронные каталоги и базы данных библиотек СО РАН"

© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)

rtvarBDview(" результаты поиска","20190607010228","4682442");

Вид поиска